title: Treatment of fibrosing cholestatic hepatitis with lamivudine.
abstract: Fibrosing cholestatic hepatitis is a histological variant of hepatitis B virus infection with a high rate of mortality. We describe a patient who acquired acute hepatitis B virus infection 8 months after renal transplantation. Clinical features of rapidly progressive liver failure, indicated by prolonged prothrombin time (57 seconds) and increased bilirubin (40.4 mg/dL) and ammonia (129 mumol/L) concentrations, were accompanied by an extremely high serum HBV DNA level (2.153 x 10(6) pg/mL). Liver biopsy specimen showed fibrosing cholestatic hepatitis with widespread balloon degeneration of hepatocytes, focal hepatocyte loss, bile stasis, periportal fibrosis, mild lymphocytic infiltration, and strongly positive immunohistochemical staining for hepatitis B surface antigen (HBsAg) and hepatitis B core antigen. Lamivudine therapy suppressed HBV DNA to < 10 pg/mL within 4 weeks, which was followed by gradual recovery of liver function from a state of hepatic precoma. Twenty-four months after the onset of hepatitis, the patient had normal prothrombin time and bilirubin, transaminase, and albumin levels. She remained HBsAg positive and hepatitis B e antigen negative. Renal allograft function was stable, with a creatinine level of 1.52 mg/dL. HBV DNA remained suppressed after 22 months of lamivudine therapy. Our experience shows that fibrosing cholestatic hepatitis and liver failure caused by HBV infection can be successfully treated with lamivudine.
authors.affiliation: Department of Medicine, University of Hong Kong, Queen Mary Hospital, China.
authors.forename: T M
authors.initials: TM
authors.lastname: Chan
authors.forename: P C
authors.initials: PC
authors.lastname: Wu
authors.forename: F K
authors.initials: FK
authors.lastname: Li
authors.forename: C L
authors.initials: CL
authors.lastname: Lai
authors.forename: I K
authors.initials: IK
authors.lastname: Cheng
authors.forename: K N
authors.initials: KN
authors.lastname: Lai
mesh_terms: D000328:Adult; D002779:Cholestasis / Q000188:drug therapy*; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005355:Fibrosis; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D019259:Lamivudine / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
chemical_list: D004279:DNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine